News

This tentative approval is for the generic bioequivalent product to Lexapro, which is offered by Forest Laboratories. Daniel Movens, CEO of Caraco Pharmaceutical Laboratories, said: “We are extremely

Under the terms of the agreement, ChemDiv will deploy the Discovery outSource platform for Orion’s discovery program, including chemical library, proprietary rational design, assay development and bioscreening. ChemDiv

The pre-specified interim Phase III (Prepare study) results relate to the study period when chemotherapy and Aranesp were administered, and specifically address the tumor response to chemotherapy at

Alcon says the active ingredient in Triesence, triamcinolone acetonide, has been used for many years to treat retinal disease. The company said that this new approval brings ophthalmologists

The conditions outlined in the panel’s recommendations related to clarifications on labeling for the device regarding small patients and those unable to be treated with anti-coagulation therapy, and

Vaccinex said that it is using its patented technology to discover and develop new monoclonal antibody therapies, and has advanced four of its lead therapeutic antibodies into preclinical

Under the terms of the agreement, Prometheus made an up-front payment which may be followed by additional payments on the successful achievement of future development milestones, including FDA

Under the agreement, signed in June 2006 and extended to cover additional work in December 2006, Arana utilized its superhumanization technology to develop humanized versions of lead antibodies

The application includes three lacosamide formulations, tablets, syrup and an intravenous injection. The proposed trade name for lacosamide is Vimpat. The new drug application (NDA) for lacosamide in